Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.

"CONFLICTS OF INTEREST Guarantor of the article: Rozanne C. de Veer, MD, and Adriaan J. van der Meer, MD, PhD. Specific author contributions: R.C.d.V., M.H.H., J.C.G., B.E.H., and A.J.v.d.M.: study concept and design. All authors: acquisition of data. R.C.d.V., M.C.v.H., M.H.H., and A.J.v.d.M.: analysis and interpretation of data, drafting of the manuscript. All authors: critical revision of the manuscript for important intellectual content. B.E.H.: obtained funding. B.E.H. and A.J.v.d.M.: study supervision. Financial support: This investigator-initiated study was supported by an unrestricted grant from Intercept Pharmaceuticals and was funded by the Foundation for Liver and Gastrointestinal Research (a not-for-profit foundation) in Rotterdam, the Netherlands. The supporting parties had no influence on the study design, data collection and analyses, writing of the manuscript, or on the decision to submit the manuscript for publication. Potential competing interests: The following authors declared that they have no conflicts of interest: R.C.v.H., M.C.v.H., and P.M.B. M.H.H. reports a speaker fee from Zambon Nederland B.V. C.C. reports receiving consulting fees from Intercept Pharmaceuticals, Cymabay, Genkyotex, and Inventiva, grant support from Arrow and Intercept Pharmaceuticals, and fees for teaching from GlaxoSmithKline. D.T. reports consulting activities for Intercept Pharmaceuticals. P.I. reports personal fees from Intercept and nonfinancial support from Bruschettini and Menarini Diagnostics. H.L.J. reports grants from and consulting work for AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Innogenetics, Merck, Novartis, Roche, Intercept Pharmaceuticals, and Janssen. F.N. reports Advisory boards for Astellas, Janssen-Cilag, AbbVie, Gilead, CAF, Intercept, Gore, BMS, Novartis, MSD, Janssen-Cilag, Promethera Biosciences, Ono Pharma, Durect, Roche, and Ferring and research grants from Roche, Ferring, and Novartis. K.D.L. reports that he is an unpaid advisor for Intercept Pharmaceuticals and Shire. A.F. reports consulting activities for Intercept Pharmaceuticals. C.Y.P. has received grant support from Takeda, speaker's fees from Tillotts and Takeda, consultancy fee from Pliant, and served as consultant for Takeda. M.J.M. reports being on advisory committees or review panels for GSK, Target, and Regeneron and grant/research support from Cymabay, Intercept, Mallinckrodt, Target, GSK, and Salix. A.P. reports consulting services for Intercept Pharmaceuticals and Novartis Pharma. A.L.M. reports advisory services for Intercept Pharmaceuticals, AbbVie, and Novartis and research funding resources from the Canadian Institutes of Health Research, Canadian Liver Foundation, American Kennel Club, Intercept Pharmaceuticals, AbbVie, and Gilead Sciences. K.V.K. reports personal fees from Gilead Sciences, Intercept Pharmaceuticals, and Novartis and grants from Gilead Sciences and Intercept Pharmaceuticals. P.J.T. receives institutional salary support from the NIHR Birmingham Liver Biomedical Research Center. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. P.J.T. has received research grant funding from the Wellcome trust, the Core Digestive Diseases Charity, Intercept Pharmaceuticals, Bristol Myers' Squibb, Innovate UK, the Medical Research Foundation, EASL, and PSC Support. He has also received speaker fees from Dr. Falk Pharma, Intercept Pharmaceuticals, and Perspectum Diagnostics. He has received consulting and advisory board fees from Dr. Falk Pharma, Intercept Pharmaceuticals, and GSK. G.M.H. reports advisory services for Intercept Pharmaceuticals, Novartis, and GlaxoSmithKline Pharmaceuticals. T.B. has received honoraria from Intercept Pharmaceuticals, Falk Foundation, Abbvie, and Norgine, and travel expenses from Gilead. G.N.D. is an advisor or lecturer for Ipsen, Pfizer, Genkyotex, Novartis, and Sobi, received research grants from Abbvie and Gilead, and has served as PI in studies for Abbvie, Novartis, Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics, Tiziana Life Sciences, Bayer, Astellas, Pfizer, Amyndas Pharmaceuticals, CymaBay Therapeutics, and Intercept Pharmaceuticals. N.K.G. is an advisor or lecturer for Gilead and has acted as a coinvestigator in studies for Abbvie, Novartis, Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics, Tiziana Life Sciences, Bayer, Astellas, Pfizer, Amyndas Pharmaceuticals, CymaBay Therapeutics, and Intercept Pharmaceuticals. X.V. received grants from Gilead, Abbvie, Dr. Phalk Pharma, and MSD and acted as a consultant for Gilead, Abbvie, and MSD. W.J.L. reports consulting services for Intercept Pharmaceuticals. B.E.H. reports grants from Intercept Pharmaceuticals, Cymabay Therapeutics, and Zambon Nederland B.V. and consulting work for Intercept Pharmaceuticals, Cymabay Therapeutics, Albireo AB, and Novartis. A.J.v.d.M. reports speakers fees from MSD, Gilead Sciences, AbbVie Pharmaceuticals, and Zambon Nederland B.V., received an unrestricted grant from Gilead Sciences, and reports travel expenses covered by Dr. Falk Pharma."

"Financial support: This investigator-initiated study was supported by an unrestricted grant from Intercept Pharmaceuticals and was funded by the Foundation for Liver and Gastrointestinal Research (a not-for-profit foundation) in Rotterdam, the Netherlands. The supporting parties had no influence on the study design, data collection and analyses, writing of the manuscript, or on the decision to submit the manuscript for publication."